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Abstract
Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to 
available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for 
physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options 
for this debilitating condition.
Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral 
neuropathy (CIPN).
Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of 
efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a 
serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on 
CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized.
Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this 
pharmacoresistant condition are discussed.
Graphic abstract
Keywords Chemotherapy-induced peripheral neuropathy · Neuronal hyperexcitability · Platinum derivatives · Paclitaxel · 
Vinca alkaloids · Bortezomib
 * Kinga Sałat 
 kinga.salat@uj.edu.pl
1 Department of Pharmacodynamics, Chair 
of Pharmacodynamics, Jagiellonian University Medical 
College, 9 Medyczna St., 30-688 Krakow, Poland
487Chemotherapy‑induced peripheral neuropathy: part 1—current state of knowledge and perspectives…
1 3
Introduction
Neuropathic pain as a major feature of neuropathy 
– General characteristics: Definition, epidemiology, 
symptoms and risk factors
According to the International Association for the Study of 
Pain’s 2011 definition, neuropathic pain is pain that arises 
as a direct consequence of a lesion or disease affecting 
the somatosensory system. This definition emphasizes the 
involvement and a key role of the somatosensory system 
in this clinical entity to distinguish it from other types 
of pain that may also be associated with disorders of the 
motor system [1].
Neuropathic pain is a chronic neurological disorder 
that represents a broad category of pain syndromes that 
include various peripheral and central nervous system 
impairments called neuropathies [2]. As a disease itself, 
neuropathic pain has a significantly negative impact on the 
sleep, everyday functioning and quality of life of patients. 
Therefore, it is also regarded as one of the triggering fac-
tors of anxiety and depression symptoms within the patient 
population [1].
A precise estimation of the incidence of neuropathic 
pain is difficult because of the lack of simple diagnostic 
criteria for large epidemiological surveys of the general 
population [1]. Epidemiological data estimate that the 
overall prevalence of neuropathic pain may be as high as 
7–8%, which corresponds to 20–25% of individuals with 
chronic pain. The values reported here may vary signifi-
cantly for particular types of neuropathic pain, such as 
postherpetic neuralgia (8–10%), painful diabetic neurop-
athy (14–26%), and neuropathic pain related to surgery 
(10–50%), multiple sclerosis (20–30%), spinal cord injury 
(30–40%) and cancer (17–19%) [3].
Clinically, neuropathic pain is characterized by so-
called positive and negative symptoms. Positive symptoms 
include various painful symptoms (tactile and thermal 
allodynia or hyperalgesia and spontaneous pain episodes), 
paresthesias, and dysesthesia (e.g., tingling, prickling, 
burning, knifelike, electrical, pulling or tightening sen-
sations). Negative symptoms usually include neurologi-
cal sensory deficits (numbness and the feeling of wearing 
socks all the time) in the painful area and are frequently 
accompanied by other deficits, such as motor or cognitive 
impairments [3–5].
Neuropathic pain is regarded as a heterogeneous and 
multidimensional clinical entity. For example, periph-
eral neuropathic pain comprises postherpetic neuralgia 
and traumatic nerve injury, but it should be noted that 
many of these patients may suffer from mixed pain syn-
dromes involving both neuropathic and nonneuropathic 
components (e.g., lumbar or cervical radiculopathies). 
Central neuropathic pain syndromes are also common, 
being observed in up to 8% of stroke patients, 30–50% 
of patients with a spinal cord injury and up to 20–25% 
of patients with multiple sclerosis or Parkinson’s disease. 
Thus, neuropathic pain patients with distinct sensory 
profiles may respond differently to available treatment 
options.
In recent years, several risk factors for neuropathy and 
neuropathic pain, including age > 60 years, female sex, 
participation in manual labor [3, 6, 7], and smoking his-
tory [8, 9] have been identified, and the number of potential 
causes of neuropathic pain is still increasing (Fig. 1). These 
causes include metabolic (diabetic), infectious (varicella 
zoster and human immunodeficiency virus infections and 
Mycobacterium leprae), traumatic, immune (Guillain–Barre 
syndrome), inherited (e.g., inherited erythromelalgia caused 
by mutations in SCN9A, which encodes the voltage-gated 
sodium channel  Nav1.7) and drug-induced factors [1].
Despite the increasing knowledge of the etiology of neu-
ropathic pain, this type of chronic pain is resistant to avail-
able analgesics in approximately 50% of patients [2, 10] and, 
therefore, is continuously a subject of considerable interest 
for physiologists, neurologists, medicinal chemists, pharma-
cologists and others searching for more effective treatment 
options for this debilitating condition.
The present review article is the first of two articles 
focused on chemotherapy-induced peripheral neuropathy 
(CIPN), which is one of the most common drug-induced 
neuropathies and is highly pharmacoresistant.
CIPN—Definition and causes
Epidemiological data presented by the World Health Organi-
zation indicate that cancer is the second leading cause of 
death worldwide following heart disease. It was responsible 
for approximately 9.6 million deaths in 2018, and the high 
mortality rate of cancer makes it a civilizational disease 
often termed as ‘a cancer epidemic’ [11, 12].
In the last decades, innovative systemic anticancer thera-
pies have been used more broadly [13]. This, together with 
progress in the early detection of tumors and the high suc-
cess rate of cancer treatment, has increased the number 
of cancer survivors. On the other hand, with the growing 
use of antitumor drugs, the prevalence of serious adverse 
iatrogenic effects caused by antitumor drugs have become 
a significant clinical issue in the cancer patient population 
[14].
CIPN is one of the most common dose-limiting adverse 
effects of many chemotherapeutic agents, such as plati-
num derivatives, taxanes, vinca alkaloids, thalidomide, 
epothilones, eribulin, ipilimumab, pembrolizumab, 
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Fig. 1  Neuropathy—Causes, risk factors and symptoms




nivolumab and bortezomib (Figs. 1, 2). It affects > 60% of 
patients receiving anticancer therapy. Although CIPN is a 
nonfatal condition, it significantly worsens patients’ quality 
of life and is usually regarded as very troublesome, as it 
might not only influence the efficacy of antitumor agents but 
also be a major cause of ongoing pain in cancer survivors 
[15–17].
At present, CIPN is often considered an unavoidable 
adverse effect of cancer chemotherapy that should be 
accepted by cancer patients and clinicians in the light of 
the extended life-span offered by these drugs. Since the 
major manifestation of CIPN comprises severe pain epi-
sodes involving tactile and thermal allodynia, hyperalgesia 
and spontaneous pain, analgesic drugs are used in patients 
exposed to CIPN-inducing antitumor therapy. However, it 
should be noted that the analgesic drugs that effectively 
relieve pain symptoms in CIPN and are used as interven-
tional treatments for pre-existing CIPN-related pain are 
very limited and that their efficacy in CIPN is significantly 
lower than that observed in other neuropathic pain types. 
Importantly, there are currently no recommended options 
for effectively preventing neuropathic pain in CIPN [19], 
and strong evidence for the utility and clinical efficacy of 
some previously tested preventive therapies (e.g., pregaba-
lin, gabapentin, duloxetine, calcium/magnesium infusion, 
amifostine, glutathione, glutamine, acetyl-l-carnitine and 
erythropoietin) is still limited [22]. The lack of efficacious 
pharmacological methods for treating CIPN and preventing 
its development [23] makes CIPN-related neuropathic pain 
a serious therapeutic gap in current medicine and pharma-
cotherapy. So far, there has been only one potential drug 
candidate for preventing the development of oxaliplatin-
induced acute and delayed CIPN, namely, calmangafodipir, 
a mitochondrial manganese superoxide dismutase mimetic, 
which is currently being studied in a placebo-controlled, 
double-blinded randomized phase III study [24]. Therefore, 
basic science research in this area and large clinical trials 
are urgently needed to establish novel and effective thera-
peutic solutions to prevent this devastating condition [17]. 
There seems to be a strong demand for a more thorough 
understanding of the etiology of CIPN, which would help 
to develop effective mechanism-based disease-modifying 
therapies. Importantly, such approaches should not nega-
tively influence the antitumor effects of the chemotherapeu-
tics used [19, 23].
Only few studies have been conducted to compare directly 
the characteristics of CIPN and other neuropathies. As men-
tioned above, these studies have shown that neuropathic pain 
in the course of CIPN is more pharmacoresistant than other 
neuropathic pain types but, on the other hand, some common 
mechanistic features have also been shown. Importantly, in a 
manner similar to other peripheral neuropathies, in CIPN the 
central nervous system is affected due to the changes in the 
barrage of peripheral input (discussed in “Central nervous 
system structures and neurotransmitters”). Therefore, many 
analgesic drugs used for alleviating CIPN-related neuro-
pathic pain are also used in neuropathic pain of other origin.
A direct comparison between diabetic neuropathy 
and CIPN has been conducted by Jin and colleagues [25] 
with respect to symptom severity and therapeutic responses. 
Using a rat model, they compared peripheral nerve dam-
age due to hyperglycemia (i.e., painful diabetic neuropa-
thy) with that caused by paclitaxel treatment. Biochemical, 
sensory and immunohistochemical parameters of cutaneous 
and sciatic nerves and the therapeutic effects of test drugs 
(alpha-lipoic acid and DA-9801) were compared in these two 
models. Sensory thresholds of animals to mechanical, heat, 
and pressure stimuli were altered by both hyperglycemia 
and paclitaxel when compared with controls. There were no 
significant differences in the biochemical markers of blood 
glutathione between diabetic rats and the paclitaxel-treated 
group. Quantitative comparisons of peripheral nerves by 
intraepidermal nerve fiber density analysis indicated that 
both groups were similar, but nerve density was significantly 
improved after alpha-lipoic acid and DA-9801 treatment in 
diabetic animals but not in the paclitaxel-treated groups. 
Sciatic nerves were less damaged in the paclitaxel-treated 
groups compared with the diabetic group. Hence, it was con-
cluded that the manifestation of neuropathy, as well as some 
therapeutic responses in CIPN may be different from those 
observed in other peripheral neuropathies.
Similarity between paclitaxel-induced CIPN model and 
short-term models of traumatic neuropathy has also been 
demonstrated [26].
Prevalence of CIPN and risk factors
As mentioned above, the survival rates of patients treated 
with antitumor agents are increasing. Hence, CIPN and 
CIPN-related neuropathic pain episodes have become a 
significant clinical issue among cancer survivors [15]. 
In general, the prevalence of CIPN resulting from dif-
ferent antitumor drugs and doses varies significantly, 
with reported prevalence rates ranging from 19 to more 
Fig. 2  Antitumor drugs that induce CIPN and the main mechanisms 
underlying CIPN [18–21]. GLT-1 glutamate transporter 1, GLAST 
GLutamate  and ASpartate Transporter, GABA γ-aminobutyric acid, 
GAT GABA transporter, TLR toll-like receptor, Glu glutamate, PAC 
paclitaxel, VIN vincristine, OXA oxaliplatin, CIS cisplatin, BOR bort-
ezomib, Nav voltage-gated sodium channels, Cav voltage-gated cal-
cium channels, Kv voltage-gated potassium channels, TRPA1 Tran-
sient Receptor Potential Ankyrin-repeat 1 channel, TRPV Transient 
Receptor Potential Vanilloid channel, TRPM8 Transient Receptor 
Potential Melastatin 8 channel, iNOS inducible nitric oxide synthase, 
IL interleukin, TNFα tumor necrosis factor α, SARM1 sterile alpha 
and TIR motif-containing protein 1, NAD + nicotinamide adenine 
dinucleotide
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than 85% [17]. It is estimated that approximately 70% 
of patients receiving chemotherapy develop CIPN dur-
ing the first month of treatment [17, 20], whereas in 
approximately 20–30% of these patients, CIPN might 
be converted to a chronic, persistent and highly pharma-
coresistant form [17, 23] that can be observed 6 months 
or even longer after therapy cessation [14, 16, 27, 28]. 
Importantly, the symptoms of these delayed complica-
tions may persist for several months and can be progres-
sively aggravated; this phenomenon in which either mild 
neuropathy worsens or a new form of CIPN develops is 
termed ‘coasting’ [21]. Since chemotherapeutics are not 
being applied when this disorder develops, coasting is a 
great challenge for clinicians; patients may be cancer-free 
but suffer from neuropathy evoked by previously received 
anticancer treatment [17].
Importantly, CIPN tends to occur both in adults and in 
younger patients. In children, most cases of CIPN are due 
to the use of vincristine and platinum derivatives, as other 
CIPN-inducing chemotherapeutics are not routinely used 
in this population [15]. It should also be noted that the 
prevalence and symptoms of CIPN seem to be age-related. 
This is thought to result from the distinct neurobiology of 
the peripheral nervous system in children and adults. The 
diameter, density and myelination of axons in the dorsal 
root ganglion significantly change during childhood to 
achieve full maturation, and this may have a strong influ-
ence on the risk of development and severity of CIPN. 
This notion is supported by previous observations that 
vincristine causes motor deficits more frequently in pedi-
atric patients than adults. The reason for this seems to be 
unclear, and several potential mechanisms, including the 
use of higher doses, altered pharmacokinetics, different 
neuronal biology, and the lack of early detection of neuro-
toxic symptoms, should be considered [15]. The treatment 
of CIPN symptoms, recovery, and the delayed effects of 
chemotherapy may also vary between adult and pediat-
ric populations. Importantly, drugs commonly used to 
treat neuropathic pain in adult patients (e.g., duloxetine) 
have not been widely studied in children. Also, physi-
cal and exercise-based therapies have not been evaluated 
in children receiving CIPN-inducing drugs. Thus, both 
the symptoms of CIPN and methods for alleviating them 
might be different between these two populations [15].
In addition to age, a number of other potential risk fac-
tors for CIPN development have been identified. These 
include the cumulative dose of a chemotherapeutic agent, 
genetic factors, a history of neuropathy before the start of 
chemotherapy (e.g., painful diabetic neuropathy or neu-
ropathy due to viral infections), impaired renal function 
with reduced creatinine clearance, and smoking history 
[9, 15, 17, 28–32].
Symptoms of CIPN
Within the patient population, numerous symptoms of 
CIPN have been identified, all of which seriously worsen-
ing patients’ quality of life [14]. It has been widely reported 
that patients who develop CIPN symptoms have significant 
difficulties in essential daily functioning. In these patients, 
unsteady gait (numbness and the loss of joint position 
sense), difficulties in fine finger movements, pain during 
walking (mechanical allodynia), and cold-exacerbated pain 
episodes (cold hypersensitivity) have been reported [17].
In general, the characteristics, time of onset and duration 
of CIPN symptoms depend on the chemotherapeutic agent 
used. Most frequently these symptoms appear after repeated 
(three to four) cycles of therapy; however, the immediate 
manifestation of CIPN symptoms has also been noted and 
in some patients, these symptoms might become permanent 
and continue for years (‘coasting’) [33, 34].
CIPN is a disease with a plethora of symptoms associ-
ated with distress (mood disorders: anxiety, depression [35], 
sleep disorders [36], cognitive impairments (chemobrain, 
a.k.a. chemofog [37, 38]), fatigue, altered taste sensation, 
and nausea), and a wide range of neurological symptoms 
present mainly in the hands and feet (e.g., numbness, tin-
gling, pain, muscle weakness and sensitivity to cold or heat) 
are also observed [14, 29, 39]. These symptoms can be clas-
sified as a motor or sensory impairments. These impairments 
typically include sensory axonal peripheral neuropathy 
(‘stocking and glove’ neuropathy), which is accompanied by 
numbness, paresthesias, ongoing/spontaneous pain hyper-
sensitivity to mechanical and thermal stimuli in the hands 
and feet [17], and motor symptoms such as distal weakness, 
reduced or absent Achilles tendon reflexes, paresthesias, 
breath dysregulation, abnormal swallowing, laryngospasm, 
muscle cramps, jaw stiffness, visual field changes, muscle 
weakness, reduced balance control and insecure gait, the 
mechanisms of which are not fully understood [20, 33, 40, 
41].
Molecular basis of CIPN
The mechanisms of action through which antitumor drugs 
induce cell death and inhibit cell proliferation are diverse 
but very well defined. It is, however, not entirely clear, if 
these effects are also responsible for the damage to nonpro-
liferating sensory neurons that underlies CIPN development. 
Available data from basic science studies indicate that in 
addition to direct cytotoxic effects, other cell-type-specific 
actions resulting from the on-target pharmacological effects 
of CIPN-inducing antitumor drugs might also contribute to 
the development of CIPN and decreased viability of sen-
sory neurons. In addition, off-target effects may also be 
implicated in CIPN development, but this issue requires 
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further and more detailed research [20]. Therefore, CIPN is 
regarded a multifactorial disorder with diverse pharmaco-
logical mechanisms, and a number of common pathologies, 
including altered ion channel functions, oxidative stress, 
axonal degeneration, impaired calcium homeostasis, neu-
roinflammation, and activation of the immune system, have 
been proposed to underlie CIPN development (Fig. 2).
Oxidative stress
In addition to controlling cellular energy production and 
energy supply, mitochondria are also involved in the regu-
lation of cell death. Neuronal mitochondrial dysfunction 
resulting in nitro-oxidative stress [42] is regarded as one 
of the most important contributors to CIPN development 
[23, 29, 43].
Several antitumor drugs, including oxaliplatin, cause 
damage to neuronal and nonneuronal mitochondria, thus 
leading to oxidative stress mediated by redox-sensitive 
TRPA1 channels. These are biomolecules that are also impli-
cated in oxaliplatin-induced mechanical and cold hypersen-
sitivity [44–50]. Oxidative stress increases the production 
of proinflammatory mediators, which further destroy mito-
chondria, enhance the production of reactive oxygen species 
and contribute to various pathological processes resulting 
from oxidative stress. These phenomena might also cause 
demyelination and disruption of the cytoskeleton of periph-
eral nerves [51].
Oxaliplatin has been shown to bind to mitochondrial 
DNA and form adducts that cannot be repaired due to the 
lack of DNA repair systems within mitochondria. These 
adducts impair mitochondrial DNA replication and tran-
scription, leading to altered protein synthesis and impaired 
respiratory chain function. In addition, vincristine dysregu-
lates neuronal mitochondria, which leads to altered neu-
ronal excitability and glial cell dysfunction. The influence 
of vincristine on mitochondria is thought to involve altered 
mitochondrial calcium signaling, and the maintenance of 
intracellular calcium homeostasis is beneficial for preventing 
CIPN [51, 52]. Paclitaxel does not directly affect mitochon-
drial DNA but induces swollen and vacuolated mitochondria 
in both myelinated and unmyelinated sensory axons, and 
these changes are accompanied by increased production of 
reactive oxygen species in the nervous system [20, 53–55].
The effect of the CIPN-inducing proteasome inhibitor 
bortezomib on mitochondria in sensory neurons has also 
been investigated [56]. In a previous study bortezomib was 
shown to alter the metabolic phenotype of sensory neurons 
and increase the production of metabolites due to aerobic 
glycolysis, thus resulting in CIPN development. It was also 
demonstrated that the targeted inhibition of the enzymes that 
maintain aerobic glycolysis might be a strategy for treating 
CIPN.
Dysregulated calcium homeostasis
Impaired calcium homeostasis and calcium signaling 
have also been shown to contribute to the development of 
oxaliplatin-, cisplatin-, vincristine-, and paclitaxel-induced 
CIPN. This calcium-dependent neurotoxic pathway is 
particularly important for oxaliplatin, of which oxalate, a 
well-known calcium chelator that contributes to the devel-
opment of oxaliplatin-induced acute form of CIPN, is a 
metabolite.
Unlike that of oxaliplatin-induced neuropathy, the contri-
bution of calcium ions to cisplatin-induced neuropathy is rel-
atively poorly understood. Cisplatin increases the expression 
of N-type voltage-gated calcium channels  (Cav2.2) [57, 58], 
but the role of these channels in the clinical manifestation of 
cisplatin-induced CIPN remains unclear. Calcium signaling 
has also been reported to participate in CIPN induced by 
paclitaxel [55], which causes rapid mitochondrial depolari-
zation and calcium release in both neuronal and nonneuronal 
cells, possibly via the activation of the mitochondrial perme-
ability transition pore [55, 59].
Increased expression of low-voltage-activated calcium 
channels (T-type channels;  Cav3.2) has also been shown in 
paclitaxel-exposed rat dorsal root ganglia. T-type current 
amplitudes are increased 7 days after paclitaxel treatment 
[60].
Maintaining intracellular calcium homeostasis attenuates 
CIPN caused by vincristine [52].
Increased protein levels of  Cav3.2 in primary afferents 
caused by decreased proteasomal degradation of  Cav3.2 
(T-type) channels is involved in bortezomib-induced neu-
ropathic pain [61].
Axonal degeneration
Animal and human studies have demonstrated that the long-
term use of the platinum derivatives [62, 63] paclitaxel [64], 
vincristine [65], and bortezomib [66] can induce axonal 
degeneration, specifically, the loss of large myelinated, small 
unmyelinated and intra-epidermal nerve fibers. The loss of 
myelin and changes to the axonal cytoskeleton may alter the 
structure and impair the function of peripheral nerves, thus 
leading to the development of sensory and motor periph-
eral neuropathy and altered pain perception. The molecular 
mechanisms of these phenomena are not fully established 
[43, 63, 67].
In patients, oxaliplatin causes moderate axonal degen-
eration and the loss of intra-epidermal nerve fibers, while 
cisplatin induces axonal degeneration of large myelinated 
fibers and myelin disruption. Similar pathologies have also 
been noted within myelinated fibers of the sciatic nerve in 
cisplatin-treated mice [33, 68].
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The degeneration of distal sensory axons, demyelina-
tion and nerve fiber loss have also been observed in vin-
cristine-, bortezomib-, and paclitaxel-induced neuropathy 
[20, 69].
A zebrafish model has been used to study the mechanisms 
underlying paclitaxel-induced neurotoxicity, sensory axon 
degeneration and the loss of touch response in the distal 
caudal fin. In zebrafish larvae, paclitaxel induces epithe-
lial damage and reduces the mechanical stress resistance 
of the skin prior to the induction of axonal degeneration. 
Reduced healing capacity of the injured skin of paclitaxel-
treated zebrafish and scratch-wounded HEK001 human 
keratinocytes has also been demonstrated. The results of this 
research demonstrated that paclitaxel induces the upregula-
tion of matrix-metalloproteinase 13 in the skin and promotes 
epithelial damage that precedes axonal degeneration [70].
In CIPN, calpains, as calcium-dependent proteases, have 
been shown to contribute to axonal degeneration [69]. Pacli-
taxel induces CIPN by altering inositol trisphosphate  (IP3) 
receptor phosphorylation and intracellular calcium flux. It 
also activates calpain proteases [71].
Recent studies have also identified a new molecular 
mechanism involving sterile alpha and TIR motif-contain-
ing protein 1 (SARM1) as an injury-inducible NADase that 
triggers axonal loss [9, 67]. The activation of SARM1 has 
been shown to contribute to Wallerian degeneration, a phe-
nomenon that occurs during axonal degeneration [72]. The 
genetic deletion of SARM1 protects axons from degenera-
tion after axotomy in mice. Turkiew and colleagues showed 
that paclitaxel-induced CIPN model mice lacking the Sarm1 
gene are resistant to distal axonal degeneration [64].
Subacute/chronic axonal loss induced by vincristine also 
involves the SARM1-mediated axonal destruction pathway, 
and the genetic deletion of SARM1 blocks the development 
of bortezomib- and vincristine-induced CIPN in mice [65, 
72].
The induction of CIPN by axonal degeneration is thought 
to be due to a loss of nicotinamide adenine dinucleotide 
(NAD +) via the SARM1 pathway [73]. Using cultured 
neurons, Geisler and colleagues found that vincristine 
and bortezomib are able to induce an axonal degeneration 
program that involves the nicotinamide mononucleotide 
NMNAT2, SARM1, and the loss of NAD + . Both drugs 
activate SARM1 and cause the SARM1-dependent deple-
tion of axonal NAD + , which is followed by local metabolic 
collapse, axonal fragmentation and axonal degeneration. Of 
note, the actions of vincristine and bortezomib involve dif-
ferent mechanisms, i.e., Wallerian degeneration occurs after 
vincristine administration, while bortezomib induces apop-
tosis [72].
It has also been suggested that vincristine might be 
responsible for an excessive increase in a NAD + direct pre-
cursor, i.e., a nicotinamide mononucleotide, rather than a 
decreased level of NAD + and that this is also likely to play 
a role in CIPN development [73].
Changes in neuronal excitability
Altered peripheral nerve excitability has also been impli-
cated in CIPN development. The altered expression and 
functional impairment of voltage-gated sodium  (Nav), 
voltage-gated potassium  (Kv), voltage-gated calcium  (Cav) 
and transient receptor potential family (TRP) channels are 
regarded as the most prominent phenomena underlying 
CIPN caused by the platinum derivatives vincristine, pacli-
taxel and bortezomib [17, 74].
Nav channels Nav 1.6 channels appear to be involved in the 
development of oxaliplatin-induced cold hyperalgesia [75], 
and the acute oxaliplatin-induced aggravation of cold hyper-
sensitivity is abolished by the administration of a selective 
 Nav1.6 inhibitor [76]. Our recent study also demonstrated 
that ambroxol, a  Nav channel inhibitor, alone or in combi-
nation with pregabalin efficiently attenuates cold allodynia 
in oxaliplatin-treated mice; this suggested that  Nav channels 
participate in this phenomenon [77]. The acute neurotoxic-
ity caused by oxaliplatin is thought to be due to the accumu-
lation of its metabolite oxalate, which is a calcium chelator. 
It immobilizes calcium ions and alters calcium-sensitive 
 Nav channel kinetics [78].
Clinically, the role of  Nav channels in CIPN development 
was also confirmed in a cisplatin-treated patient in whom 
lacosamide, an antagonist of  Nav channels, significantly alle-
viated the severe painful symptoms of CIPN [79]. However, 
it should be noted that in addition to  Nav channels, other 
mechanisms have been implicated in cisplatin- and carbo-
platin-induced CIPN. Avan and colleagues demonstrated 
that both these drugs are neurotoxic because they induce 
DNA adduct accumulation and the inhibition of DNA repair 
pathways, such as the extracellular signal-regulated kinase 
1/2, c-Jun N-terminal kinase/stress-activated protein kinase, 
and p38 mitogen-activated protein kinase pathways, which 
ultimately results in apoptosis [78].
The gene expression and currents of  Nav 1.7 channel 
 (Nav1.7) are increased in the dorsal root ganglia of pacli-
taxel-treated rats. Similarly, gain-of-function mutations in 
human  Nav1.7 channels have also been noted in paclitaxel-
treated patients [80, 81].
Kv channels In isolated rat sciatic nerves, oxaliplatin causes 
broadening of the repolarization phase, induced repeti-
tive firing and afterhyperpolarization, and these effects 
are caused by its effect on  Kv channels. After oxaliplatin 
and paclitaxel treatment, decreased expression of two-pore 
domain  K+  channels (TREK-1 and TRAAK) is observed 
in the rodent dorsal root ganglia [20]. In mice, riluzole, an 
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activator of TREK-1 and TRAAK, prevents both sensory 
and motor deficits induced by oxaliplatin and attenuates the 
depression-like symptoms induced by oxaliplatin. Riluzole 
has no negative effect on the antiproliferative capacity of 
oxaliplatin in human colorectal cancer cells and does not 
reduce its anticancer effect in a mouse model of colorec-
tal cancer. Moreover, riluzole decreases the viability of a 
human colorectal cancer cell line in vitro and inhibits polyp 
development in vivo. These data confirm the important role 
of TREK-1 and TRAAK in CIPN [82, 83].
A potential role for the potassium channel SK3 (KCNN3 
gene) in oxaliplatin-induced CIPN has also been suggested. 
In a preclinical model, a slight association between CIPN 
and CAG repeat polymorphisms in the KCNN3 gene was 
shown, but such an association between CIPN and KCNN3 
polymorphisms was not shown in patients [84]. In a mouse 
study, the activation of  Kv7 channels reduced the symptoms 
of CIPN induced by oxaliplatin and paclitaxel [85]. In line 
with this, minoxidil, a potassium channel opener alleviates 
the signs of paclitaxel-related CIPN [17].
Cav channels Increased expression of  Cavα2δ – 1 subunit 
mRNA and protein in the spinal cord 2 and 4 days after oxali-
platin treatment contributes to acute cold hypersensitivity in 
rodents [86]. A crucial role of the  Cavα2δ − 1 subunit in the 
development of oxaliplatin-induced acute and delayed cold 
hypersensitivity has been shown in mice [77] and rats [86].
The short- and long-term effects of the exposure of  Cav 
channels to oxaliplatin have been investigated in rat small 
dorsal root ganglia.  Cav channel currents are concentration-
dependently reduced by oxaliplatin. Moreover, differential 
time-dependent effects of oxaliplatin on calcium currents 
have been noted. Acute treatment with oxaliplatin leads to 
a reduction in P/Q-, T-, and L-type  Cav channel currents, 
while there is no effect of this acute treatment on N-type 
 Cav channel currents. In contrast to this, prolonged (24 h) 
exposure of dorsal root ganglia neurons to oxaliplatin sig-
nificantly increases L- and T-type  Cav channel currents. 
Increased L- and T-type  Cav channel protein levels in dorsal 
root ganglion neurons have also been noted 24 h after oxali-
platin exposure [87]. Analogous research showing a crucial 
role of N-type  Cav channels in cisplatin-induced polyneu-
ropathy was conducted. This study showed that cisplatin 
reduced  Cav channel currents in a concentration-dependent 
manner. Subtype-specific measurements of  Cav channel cur-
rents showed the differential effects of this platinum deriva-
tive on  Cav channel subtypes. While the currents of P/Q-, 
L- and T-type  Cav channels were reduced, those of N-type 
 Cav channels were increased. Further analyses revealed an 
increase in N-type  Cav channel protein levels in dorsal root 
ganglion neurons 24 h after cisplatin administration. Cispl-
atin activated caspase-3 and this effect were prevented by 
ω-conotoxin MVIIA, an N-type  Cav channel inhibitor [58].
A recent study [88] showed that cisplatin-induced neuro-
toxicity might be due to functional alterations in  Cav chan-
nels but not to structural damage to these channels, as no 
morphological signs of damage, apoptosis or necrosis were 
noted in dorsal root ganglion cells exposed to cisplatin for 
26 days.
Increased levels of  Cav channel mRNA within dorsal root 
ganglion neurons have been demonstrated in paclitaxel-
treated mice, and  Cav channel antagonists (gabapentin and 
ethosuximide) effectively reduce hyperalgesia in rodents 
with paclitaxel- and vincristine-induced CIPN [17]. Many 
studies have confirmed a crucial role of N-type and T-type 
 Cav channels in paclitaxel-induced CIPN [74] as well as a 
key role of T-type  Cav channels in CIPN caused by vincris-
tine [89].
A mouse study showed that the inhibition of the protea-
somal degradation of T-type  Cav channels by bortezomib 
and bortezomib-induced increases in the levels of USP5, a 
deubiquitinating enzyme that specifically inhibits the pro-
teasomal degradation of T-type  Cav channels, increases the 
protein levels of T-type  Cav channels in nociceptors. The 
systemic administration of T-type calcium channel blockers 
reverses CIPN caused by bortezomib. Also in ND7/23 cells, 
bortezomib increases the protein levels of T-type  Cav chan-
nels and T-channel-dependent currents [61].
TRP channels Altered expression and function of several 
thermo- and mechanosensitive Transient Receptor Potential 
(TRP) channels, namely, vanilloid 1 (TRPV1), Ankyrin-
repeat 1 (TRPA1), and melastatin 8 (TRPM8) [43, 46, 47, 
90, 91], and TRPA1- and TRPV4-dependent oxidative stress 
have also been reported in CIPN [47, 92–95].
In mice, oxaliplatin-induced rapid-onset cold hypersen-
sitivity is ameliorated by TRPA1 blockade [49, 96]. Oxali-
platin stimulates TRPA1 but does no effect on TRPM8 or 
TRPV1 channels either in vivo or in vitro. These responses 
are caused by the oxaliplatin metabolite—oxalate. In human 
TRPA1-expressing cells, oxaliplatin and oxalate cause 
TRPA1 sensitization to reactive oxygen species (ROS) by 
inhibiting prolyl hydroxylases, which is consistent with the 
observed cold hypersensitivity. Hence, it is thought that 
oxaliplatin-induced acute cold hypersensitivity is caused by 
TRPA1 sensitization to ROS via enzyme inhibition, which 
enables TRPA1 to convert ROS signals into cold sensitivity 
[47, 96].
Oxaliplatin-induced TRPA1 activation occurs via a 
glutathione-sensitive mechanism [94, 96]. In a study by 
Miyake and colleagues, a high concentration of oxaliplatin 
increased intracellular calcium concentration in human (h) 
TRPA1-expressing HEK293 cells. Oxaliplatin also induced 
the rapid generation of hydrogen peroxide and evoked ROS-
mediated cysteine oxidation-dependent hTRPA1 activation. 
The observed calcium influx was prevented in the presence 
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of glutathione. In contrast to this, a lower concentration of 
oxaliplatin (100 μM) did not increase the intracellular cal-
cium concentration but caused the cold-induced cysteine 
oxidation-dependent opening of human TRPA1 channels. 
These concentration-dependent biochemical mechanisms of 
the observed phenomena were different [96].
Paclitaxel activates and sensitizes the function of TRPV1 
and TRPV1 antagonists induced analgesia in paclitaxel-
related CIPN [17]. TRPA1 and TRPM8 channels have also 
been implicated in paclitaxel-induced neurotoxicity and 
CIPN-related pain behavior in mice [97]. A recent study 
also confirmed a role of TRPV4 channels in CIPN caused 
by paclitaxel. In this study [93], the administration of pacli-
taxel resulted in strong  IP3-mediated calcium signals ampli-
fied by calcium entry through TRPV4 channels. Blocking 
calcium influx through TRPV4 channels reduced cell death 
in cultured dorsal root ganglia neurons, and the pretreat-
ment of mice with the TRPV4 inhibitor (HC067047) prior 
to paclitaxel injection prevented both the neurotoxic effects 
of paclitaxel on electrophysiology and behavior [93].
The exposure of isolated sensory neurons to vinca alka-
loids produces an inward sodium current that depolarizes 
these neurons, resulting in neuronal firing. These neuronal 
effects are regulated by TRPA1 channels, and hypersensitiv-
ity to painful stimuli in response to vinca alkaloid adminis-
tration is reduced in TrpA1 mutant flies and mice [98].
TRPA1 channels are also involved in bortezomib-induced 
neurotoxicity, and the selective blockade of these channels 
by Phα1β (a peptide from the venom of the armed spider 
Phoneutria nigriventer) and CTK 01512-2 (a recombinant 
form of the peptide) reduces the TRPA1-dependent neuro-
pathic pain-like responses induced by bortezomib [99].
Activation of the immune system and neuroinflammation
Antitumor drugs modulate the immune system, and this 
constitutes one of the most important mechanisms underly-
ing tumor cell destruction. Simultaneously, the activation 
of the immune system, the recruitment of immune cells and 
neuroinflammation are regarded as a potential significant 
contributors to the development of CIPN [17, 100–104].
An increase in the peripheral levels of proinflammatory 
cytokines, changes in immune signaling pathways and a 
strong correlation between inflammation and peripheral 
neuropathy caused by chemotherapy have been observed in 
numerous studies [102, 105, 106].
It was recently shown that vincristine dysregulates genes 
associated with immunological processes, whereas oxalipl-
atin causes the dysregulation of genes associated with neu-
ronal function. Cisplatin influences the expression of genes 
implicated in both inflammatory and neuropathic patholo-
gies [102]. The infiltration of leukocytes into the nervous 
system of animals with CIPN symptoms and peripheral 
and central glial cell activation have also been observed. 
These alterations are dependent on the chemotherapeutic 
drug used, its dose, the treatment schedule, and the therapy 
duration. There is, however, still limited evidence for such 
phenomena from human studies [105].
Cytokines and  chemokines Increased production and 
release of cytokines [e.g., interleukins (IL): IL-1β, IL-6, 
IL-8, tumor necrosis factor α (TNFα), and interferon γ 
(IFN-γ)] and chemokines (e.g., CCL2, and CXCL12, 
CCL11, CCL3, and CCL4) and decreased expression of 
anti-inflammatory cytokines (IL-10 and IL-4) are observed 
after the administration of several chemotherapeutics 
including paclitaxel, cisplatin and vincristine. IL-1, TNFα, 
and IL-6 not only cause axonal damage but also facilitate 
neuron-immune communication and increase the release of 
bradykinin, serotonin, and histamine. These mediators are 
able to augment proinflammatory processes and act as sen-
sitizers for nociceptors, thus playing a crucial role in the 
progression of CIPN. Increased concentrations of cytokines 
and chemokines in the dorsal root ganglia and spinal cord 
induce alterations in the Schwann cells of peripheral axons, 
satellite cells in the dorsal root ganglia, and astrocytes in 
the spinal cord, which all contribute to CIPN development 
[102, 106–111].
Recently, using models of CIPN induced by paclitaxel 
and oxaliplatin, it was shown that the IL-8 signaling pathway 
is involved in neuroinflammation that results in a progres-
sive neural sensitization [108]. The levels of interleukin IL-6 
and IL-6 receptors in women after breast cancer treatment 
have also been investigated, and these studies revealed that 
the IL-6 signaling pathway may be an important biological 
mechanism associated with the persistence of the painful 
symptoms of CIPN, which may have potential implications 
for the management of CIPN symptoms [112].
Oxaliplatin administration increases the mRNA levels of 
proinflammatory cytokines and chemokines, and this effect 
is strongly correlated with the development of mechanical 
hypersensitivity observed in rats. Oxaliplatin-induced pain is 
accompanied by the upregulation of PI3K-mTOR, enhanced 
mTOR-mediated signals and increased ERK phosphoryla-
tion. Taken together, these findings suggest that the mecha-
nism of the development of oxaliplatin-induced neuropathy 
resembles that of inflammatory pain [113].
Crosstalk between the nervous system and the immune 
system during chemotherapy is well known to occur, and the 
upregulation of chemokines is a key phenomenon that modu-
lates this effect. Chemokines, which were originally identi-
fied as regulators of peripheral immune cell trafficking, are 
expressed on neurons and glial cells in the central nervous 
system. As such, they are regarded as important contributors 
to pain signaling in CIPN. The expression of chemokines 
and their receptors, (e.g., CX3CL1/CX3CR1, CCL2/CCR2, 
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CXCL1/CXCR2, CXCL12/CXCR4 and CCL3/CCR5) is 
altered in CIPN [114, 115].
The C–C motif chemokine ligand 2 (CCL2, also known 
as monocyte chemoattractant protein 1, MCP1) [2] and its 
receptor CCR2 are increased in the small dorsal root gan-
glion neurons of paclitaxel-treated rats with CIPN symp-
toms. CCR2 gene knockdown or CCR2 blockade reduces 
neuropathic pain in mice [17, 116].
In addition to increasing the level of CCL2, paclitaxel 
also increases the level of CCL3 in the lumbar dorsal root 
ganglion [109].
Increased levels of CCL2 and CCR2 in the dorsal root 
ganglia have also been observed to be accompanied by 
mechanical hypersensitivity in oxaliplatin-treated rats [117].
Using a mouse model of vincristine-induced CIPN, Mon-
tague and colleagues demonstrated that CCL2/CCR2 sign-
aling plays a crucial role in the development of allodynia 
in CX3CR1-deficient mice. They suggested that this effect 
might be due to an interaction between CX3CR1 and CCR2 
receptors in monocytes [118].
Vincristine and paclitaxel upregulate C-X-C motif 
chemokine ligand 12 (CXCL12) in the dorsal horn gan-
glia. This chemokine is a ligand of CXCR4 (CD184, C-X-C 
chemokine receptor type 4). CXCL12 can be released from 
the central terminals of dorsal root ganglion neurons into 
spinal cord dorsal horn neurons and functions as an attract-
ant for T-lymphocytes and monocytes. The activation of 
CXCR4 increases the intracellular calcium concentration 
and stimulates the chemotaxis of immune cells to the site 
of inflammation [17].
Immunological ligands and  receptors Toll-like receptors 
(TLR) are transmembrane proteins that function as sensors 
of a diverse range of endogenous and exogenous substances 
that are potentially harmful to the body. They are widely 
expressed on immune cells, enterocytes, sensory neurons 
and glial cells. When activated, they modulate inflamma-
tory responses in body tissues to detect various pathogens. 
TLR4 is specialized to detect bacterial pathogens, and TLR3 
detects viral pathogens. TLR4 is also activated in many neu-
ropathic pain states [119], including those associated with 
CIPN caused by paclitaxel [120–125], oxaliplatin [126, 
127], cisplatin [6, 128] and vincristine [129]. TLR4 acti-
vation by chemotherapeutics is responsible for the increase 
in proinflammatory cytokine expression in the peripheral 
and central nervous systems. TLR4 signals that promote the 
expression of MCP-1 are increased in the dorsal root gan-
glia of rats with paclitaxel-induced hyperalgesia, and this 
effect can be prevented by cotreating the animals with TLR4 
antagonists during chemotherapy [116].
Similarly, mice with genetic TLR4 or TLR3 knockout 
do not develop hyperalgesia after treatment with cisplatin 
[17, 110].
Sex-dependent differences in pain sensitivity were shown 
recently in paclitaxel-treated rats with CIPN symptoms 
[130], and it has been demonstrated that the lipopolysaccha-
ride-induced activation of spinal TLR4 mediates mechanical 
allodynia in male mice but not in female mice. This receptor 
also plays a sex-specific role in inflammatory and neuro-
pathic pain in male mice, and this sex-specific response is 
limited to the spinal cord [131].
The cellular and molecular mechanisms of TLR9 signal-
ing in CIPN caused by paclitaxel were investigated using 
Tlr9-deficient mice of both sexes. It was found that in male 
mice but not in female mice, a Tlr9 mutation attenuated 
the development of neuropathic pain caused by paclitaxel. 
Moreover, a TLR9 antagonist injected intraplantarly allevi-
ated paclitaxel-induced mechanical allodynia only in male 
wild-type mice. Taken together, this study shows the involve-
ment of sex-dimorphic TLR9 signaling (in both the spinal 
cord and the periphery) in CIPN and suggests that TLR9 
signaling pathway promotes CIPN in male mice. It was pos-
tulated that the activation of TLR9 in macrophages in male 
mice results in the release of proinflammatory cytokines 
and chemokines and that this is the basis for CIPN-related 
mechanical allodynia in male mice [120].
Immune cells T-cells Paclitaxel-induced mechanical allo-
dynia is prolonged in T-cell-deficient (Rag1−/−) mice com-
pared to their wild-type littermates, and it was demonstrated 
that CD8 + T-cells in the dorsal root ganglia are critical for 
recovery from CIPN [110, 132]. Similar results have been 
shown for cisplatin [133]. T cells are also involved in the 
preventive effects of histone deacetylase six inhibitors on 
cisplatin-induced mechanical allodynia and mitochondrial 
deficits in dorsal root ganglion neurons [134].
On the other hand, in male C57BL/6  J mice treated 
with paclitaxel or oxaliplatin, significant mechanical allo-
dynia is accompanied by increased circulating CD4 + and 
CD8 + T-cells [109].
Macrophages  The intestinal mucosa is the largest 
immune organ and contains an abundance of macrophages, 
which are key cells for homeostasis maintenance. Mac-
rophages regulate the development of behavioral hyper-
sensitivity and the loss of distal epidermal nerve fibers and 
hence play an important role in paclitaxel-related neuropathy 
[116, 135].
It was recently postulated that the gut microbiota may 
influence CIPN through macrophages [110], and after chem-
otherapy, the number of CD11b + CD45hi cells, which are 
presumably macrophages, is significantly lower in the dorsal 
root ganglia of mice that receive water containing antibiotics 
than those receiving water alone [136].
In rats, intravenous immunoglobulins are effective as a 
therapeutic option, reducing macrophage infiltration and the 
severity of bortezomib-induced CIPN [103].
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Astrocytes As the most abundant cells in the CNS, astro-
cytes participate in diverse functional processes, including 
brain metabolism and neuronal transmission. The activa-
tion of astrocytes and the release of modulators from these 
stimulated cells have been implicated in neuropathic pain 
of various origins [110], including paclitaxel-induced CIPN 
[107, 109].
Microglia The role of spinal microglia in neuropathic 
pain syndromes is complex [137] and, at least for CIPN, 
is not completely understood. Investigations of the role of 
microglia in CIPN have presented opposing findings. Some 
researchers gave reported increased microglial activation 
in response to vincristine and paclitaxel administration 
[138–141]. On the other hand, there are also data that sug-
gest that microglia do not play a significant role in CIPN, at 
least when compared to the pivotal role of astrocytes in this 
clinical entity [142].
It should be emphasized that microglia, as immune 
cells, are an abundant source of pain-associated substances, 
including IL-1β, IL-6, and TNFα. Minocycline, an inhibi-
tor of macrophages, monocytes and microglia, as well as a 
matrix metalloproteinase-9 (MMP-9) inhibitor, attenuates 
mechanical hyperalgesia induced by oxaliplatin and pacli-
taxel [17, 110].
In cisplatin-treated mice that show symptoms of mechani-
cal allodynia and sensory deficits, the activation of micro-
glia, but not astrocytes, in the spinal cord is observed. This 
is accompanied by increased mRNA levels of inflammatory 
state-related molecules (IL-1β, IL-6, TNFα, and inducible 
nitric oxide synthase). Minocycline alleviates cisplatin-
induced behavioral signs of neuropathy in this mouse model 
[143].
A large number of studies have focused on the connec-
tion of the gut microbiota to chemotherapy-induced diar-
rhoea or mucositis [110], but there is also recent evidence 
for the involvement of the gut microbiome and impaired 
microglia function in the development of CIPN [104, 136, 
144]. The microbiota is critical for controlling microglial 
maturation and function, and the treatment of adult mice 
with antibiotics results in impaired maturation and innate 
immune functionality of these immune cells in the brain. 
It has been hypothesized that the gut microbiome connects 
the microbiome-gut-brain and neuroimmune-endocrine axes, 
and this network might influence key components involved 
in CIPN.
Recently, a potential role of the gut microbiome in the 
development of CIPN caused by paclitaxel was suggested 
[138]. Spinal microgliosis is also involved in paclitaxel-
induced pain and a link between the gut microbiota, micro-
glial activation and neuroinflammation in CIPN has been 
reported [144]. In this study, paclitaxel decreased the 
amount of beneficial bacteria such as Akkermansia mucin-
iphila OTU, which was previously shown to promote the 
integrity of the epithelial cell layer and improve barrier 
function [144]. It was then hypothesized that chemotherapy 
causes barrier dysfunction, resulting in increased systemic 
exposure to bacterial products and metabolites, which in turn 
promotes systemic inflammation and pain. Also, oxaliplatin-
induced mechanical hyperalgesia is reduced in germ-free 
mice and in mice pretreated with antibiotics, which further 
suggests that the gut microbiota promotes the development 
of oxaliplatin-induced mechanical hypersensitivity and neu-
roinflammation. These effects appear to be mediated, in part, 
by TLR4 expressed on macrophages [136].
Schwann cells Schwann cells are glial cells in the periph-
eral nervous system that form a thin myelin sheet around the 
axons of motor and sensory neurons, thus enabling salta-
tory conduction of action potentials. Furthermore, they are 
a source of vasoactive mediators and play an important role 
in the recruitment of immune cells from the vasculature. 
Schwann cells have been shown to express various TLRs 
and play a key role in neuroinflammation resulting from the 
administration of antitumor drugs [29, 110]. Recently, Imai 
and colleagues investigated the effects of antitumor drugs 
on Schwann cells. They showed that the exposure of pri-
mary cultured rat Schwann cells to paclitaxel, cisplatin, or 
oxaliplatin at concentrations lower than those required to 
induce neurotoxicity in cultured rat dorsal root ganglion neu-
rons induced cytotoxicity and reduced myelin basic protein 
expression. These chemotherapeutic drugs disrupted myelin 
formation by Schwann cells. Platinum derivatives induced 
mitochondrial dysfunction in cultured Schwann cells, while 
paclitaxel led to the dedifferentiation of Schwann cells into 
an immature state characterized by increased expression of 
p75 and galectin-3. In line with this, in the mouse sciatic 
nerve, repeated injection of paclitaxel increased the expres-
sion of p75 and galectin-3 in Schwann cells [145].
Central nervous system structures and  neurotransmit‑
ters In the course of CIPN structural damage to the 
peripheral nervous system induces abnormal central nerv-
ous system processing. The involvement of the brain and 
spinal cord in CIPN development has become a subject of 
extensive studies but at present the impact of CIPN on brain 
structures and levels of central nervous system neurotrans-
mitters is still understudied.
To elucidate the role of central nervous system neurons 
in altered behavioral sensitivity seen during chronic pain 
conditions Samineni and colleagues [146] studied sponta-
neous and thermally-evoked firing patterns of ventrolateral 
periaqueductal gray neurons in rats treated with paclitaxel. 
In this research, ventrolateral periaqueductal gray neurons 
displayed increased neuronal activity and changes in ther-
mal pain-evoked neuronal activity. This involved elevated 
levels of spontaneous firing and increased responsiveness to 
non-noxious stimuli (allodynia) as well as noxious thermal 
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stimuli (hyperalgesia) as compared to controls. Furthermore, 
after paclitaxel treatment only excitatory neuronal responses 
were observed to both non-noxious and noxious thermal 
stimuli. Systemic administration of gabapentin induced sig-
nificant dose-dependent decreases in the elevated spontane-
ous and thermally-evoked ventrolateral periaqueductal gray 
neuronal firing to both non-noxious and noxious thermal 
stimuli in paclitaxel-treated rats but not in naïve rats. These 
results showed a strong correlation between behavioral 
hypersensitivity to thermal stimuli and increased firing of 
ventrolateral periaqueductal gray neurons in allodynia and 
hyperalgesia that occur after paclitaxel administration.
The reorganization of neural circuits in the brain in CIPN 
have been also observed by Ferris and colleagues [147]. 
They conducted an imaging study to evaluate the impact 
of paclitaxel treatment (8 days) on brain neural circuitry in 
rats. Paclitaxel-treated rats were more sensitive to a cold 
stimulus compared to controls. Brain areas involved in the 
emotional and motivational responses to chronic pain were 
also impacted by paclitaxel treatment. Affected brain regions 
included the prefrontal cortex, amygdala, hippocampus, 
hypothalamus and the striatum/nucleus accumbens. This 
study confirmed central nervous system effects of chemo-
therapy and showed that neuropathic pain is modulated by 
emotion and motivation, and influences activity of the peri-
aqueductal gray and brainstem to modulate pain perception.
The central changes observed during paclitaxel-induced 
CIPN are likely to be caused by the neurotoxic effects trig-
gered by this antitumor drug at the periphery because pacli-
taxel has a very low ability to cross the blood–brain barrier 
[148].
CIPN-related alterations are also observed at the spinal 
cord level and paclitaxel-injected animals showed increased 
spontaneous activity of wide-dynamic range neurons and 
decreased expression of glutamate transporters in the lumbar 
spinal dorsal horn. These results suggest a state of increased 
excitability that develops in spinal pain-signaling neurons 
as a consequence of decreased glutamate clearance. These 
changes in dorsal horn contribute to the hyperresponsiveness 
to sensory stimuli seen in animals treated with paclitaxel 
and may play a role in pain seen in patients on paclitaxel 
therapy [149].
Reorganization of some brain areas, including the fron-
tal lobe, insular cortex, somatosensory cortex, thalamus, 
periaqueductal gray and precuneus has been demonstrated 
in CIPN. A study using fMRI explored central pain pro-
cessing in myeloma patients with CIPN. This study showed 
that painful stimuli delivered to neuropathy-affected and 
symptom-free sites in patients suffering from CIPN evoked 
differential activation of distinct cortical regions [150].
An association between cerebral resting-state perfusion 
and CIPN symptoms was demonstrated in patients with 
breast cancer and CIPN symptoms. These results suggest 
that gray matter density decrease and associated perfusion 
decrease may interfere with CIPN-symptoms and patient 
symptom perception. Individuals showing gray matter den-
sity decrease may report less severe symptoms of CIPN, 
while showing less CIPN symptom-related perfusion change 
[151].
Altered levels of several neurotransmitters, such as 
catecholamines, histamine, serotonin, glutamate and 
γ-aminobutyric acid (GABA), are associated with CIPN 
caused by vincristine [152, 153], paclitaxel [154], oxalipl-
atin [155–157] and bortezomib [158].
The analgesic effect mediated by monoamines: seroto-
nin and noradrenaline, is due to the blockade of nociceptive 
transmission at the spinal dorsal horn. This activity is inde-
pendent of their antidepressant effect. Antidepressants that 
act at serotonin and noradrenaline reuptake are clinically 
relevant in CIPN treatment [19].
Using an animal model of paclitaxel-induced CIPN, 
increased activity of serotoninergic neurons of the rostroven-
tromedial medulla has been demonstrated in rats. The immu-
nohistochemical analysis of serotonin showed increased 
expression at the superficial dorsal horn (laminae I–II) and 
higher levels of 5-HT3 receptors in the superficial dorsal 
horn (laminae I–II) of paclitaxel-injected animals. The 
intrathecal administration of the 5-HT3 receptor antagonist 
(ondansetron) reversed mechanical and cold hypersensitivity 
of paclitaxel-treated rats. These results indicate that CIPN is 
associated with increased recruitment of descending sero-
tonergic modulation from the rostroventromedial medulla 
which affects the spinal serotoninergic system and might 
account for pain hypersensitivity mediated by spinal 5-HT3 
receptors [159].
Animal models of neuropathic pain revealed that 
noradrenaline is a neurotransmitter that plays an important 
role in the inhibition of this chronic pain type. The increase 
of noradrenaline in the spinal cord by reuptake inhibition 
directly attenuates neuropathic pain through α2-adrenergic 
receptors. Moreover, noradrenaline acts within the locus 
coeruleus and improves the function of the impaired 
descending noradrenergic inhibitory system. Serotonin and 
dopamine may reinforce the noradrenergic effects to inhibit 
neuropathic pain [160].
The role of descending noradrenergic modulation of 
spinal nociceptive transmission in CIPN was studied 
in paclitaxel-treated rats [26]. It has been shown that in 
the paclitaxel-induced CIPN rat model, the descending 
noradrenaline-mediated inhibition affecting nociceptive 
transmission at the spinal cord is potentiated. It has been 
suggested that the enhanced noradrenergic inhibition during 
CIPN may represent an adaptive mechanism of the descend-
ing noradrenergic pain control system to the increased 
peripheral nociceptive input. Pharmacological stimulation 
of α2-adrenergic receptors at the spinal cord level using 
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noradrenergic drugs (e.g., reboxetine, clonidine) may, there-
fore, represent a promising therapeutic opportunity to treat 
CIPN-related pain [26].
Glutamate transporters, such as glutamate transporter 
1 (GLT-1) and glutamate aspartate transporter (GLAST, 
EAAT1), are abundantly expressed in astrocytes, where they 
act to remove synaptically released glutamate from the syn-
aptic cleft [161]. These transport proteins have been shown 
to be downregulated in activated astrocytes, and this results 
in impaired functioning of these proteins, leading to neuronal 
hyperexcitability. Importantly, the downregulation of both 
GLT-1 and GLAST has been observed in paclitaxel-treated 
[149, 162, 163], oxaliplatin-treated [164] and bortezomib-
treated neuropathic rats [165]. In our recent study [166], a 
single dose and repeated doses of ceftriaxone, a beta-lactam 
antibiotic that acts by upregulating GLT-1 expression, thus 
increasing glutamate reuptake in the CNS [167–169], was 
tested for its ability to attenuate early-phase and late-phase 
tactile allodynia and cold hyperalgesia in oxaliplatin-treated 
mice. The repeated intraperitoneal administration of 200 mg/
kg ceftriaxone prevented the development of late-phase 
tactile allodynia, but ceftriaxone showed no antiallodynic 
properties in the cold plate test. These results confirmed pre-
vious findings showing that ceftriaxone (through increased 
GLT-1 expression) affected mechanical rather than thermal 
(cold) allodynia, which suggests that the biological functions 
of GLT-1 are more associated with the regulation of the 
mechanical nociceptive threshold than the cold nociceptive 
threshold [170].
In addition to decreased astrocytic glutamate reuptake 
due to GLT-1 and GLAST hypofunction, increased synaptic 
γ-aminobutyric acid (GABA) reuptake resulting from the 
enhanced GAT-1 function should be considered as a phe-
nomenon implicated in CIPN development. The evidence 
for this is mainly based on the observed significant antial-
lodynic and antihyperalgesic effects of GAT-1 inhibitors in 
rodent models of CIPN. Decreased GABAergic neurotrans-
mission due to excessive IL-17 levels in the spinal cord has 
been linked to CIPN caused by paclitaxel [171], and the 
inhibition of GABA reuptake with by NO-711, a selective 
GABA transporter isoform 1 (GAT-1) inhibitor [172], pre-
vents the development of thermal hyperalgesia and allodynia 
in paclitaxel-treated mice. NO-711 is also therapeutically 
effective for pre-existing CIPN [173]. Also, GABAergic pre-
cursor cell transplants reverse paclitaxel-induced mechanical 
hypersensitivity [174].
In paclitaxel-treated animals, the enhancement of GAT-1 
protein expression, decreased GAT-3 expression, increased 
global GABA uptake, as well as suppression of GABAer-
gic tonic inhibition in the spinal dorsal horn are also noted. 
Paclitaxel-induced neuropathic pain was significantly attenu-
ated by the intrathecal injection of a GAT-1 inhibitor but not 
a GAT-3 transporter inhibitor. These findings confirm that 
targeting GAT-1 transporters for reversing disinhibition in 
the spinal dorsal horn may be a useful approach for treating 
paclitaxel-induced neuropathic pain [175].
In oxaliplatin-treated rats, the elevation of IL-1β, IL-6, 
and TNFα levels in the periaqueductal gray matter and the 
upregulation of IL-1β, IL-6, and TNFα receptor expres-
sion in the plasma membrane in the periaqueductal gray of 
oxaliplatin-treated rats coincides with decreased GABAergic 
neurotransmission. The behavioral symptoms noted in these 
animals include tactile and cold allodynia. The blockade 
of proinflammatory cytokine receptors results in restored 
GABA function and the attenuation of mechanical and cold 
hypersensitivity [176].
The effect of tiagabine, a highly selective GAT-1 inhibi-
tor, on oxaliplatin-induced neuropathic pain in mice was 
assessed [177]. The intraperitoneal administration of 
tiagabine at doses of 4 mg/kg and 8 mg/kg attenuated tactile 
allodynia in the von Frey test both 3 h (acute phase of CIPN) 
and 7 days (late phase of CIPN) after oxaliplatin injection. 
Tiagabine was not effective in reducing cold hyperalgesia in 
either the acute phase or the late phase.
The effect of non-GAT-1 inhibitors on the behavioral 
symptoms of CIPN is less known; however recent studies 
have shown that preferential inhibitors of mouse GAT3/4 
might attenuate tactile allodynia but not cold allodynia in 
oxaliplatin-treated mice [178].
Concluding remarks
Since the survival rate of patients treated with antitumor 
agents is increasing, CIPN is considered to be a significant 
cause of decreased quality of life among cancer survivors. 
The number of analgesic drugs that effectively relieve pain 
symptoms and are used as an interventional treatment for 
pre-existing CIPN-related pain is very limited, and the effi-
cacy of these drugs in CIPN is significantly lower than that 
in other neuropathic pain types. Despite our growing knowl-
edge regarding the mechanisms underlying CIPN, this clini-
cal entity is still not preventable. Currently, animal models 
of CIPN are widely used to investigate CIPN pathophysiol-
ogy and to develop potential novel therapies for this debili-
tating condition. These preclinical models aim to reflect the 
impairments observed in CIPN in humans and they provide a 
deeper insight into the mechanisms underlying the initiation 
and maintenance of CIPN.
On the other hand, the lack of translational progress 
in pain studies has been observed, recently. Basic science 
knowledge obtained using both in vivo and in vitro models 
has not resulted in a dynamic development of novel drugs 
for CIPN and even a broader use of genetically-manipulated 
animals to study CIPN or assays that more closely resemble 
clinical picture of CIPN-related pain states has not increased 
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the effectiveness of drug discovery and development of 
analgesics for CIPN. Therefore, a careful re-examination of 
animal models of CIPN-related pain seems an urgent need.
Pain is a complex phenomenon which is affected by a 
wide range of modulatory factors, including sex, genotype 
and social communication, and all of them must be consid-
ered when translating results obtained in animal model to 
humans [179–182]. In addition to genetic and neurochemical 
differences between rodents and humans, there are also neu-
roanatomical differences in pain pathways between rodents 
and humans (i.e., rodent and primate dorsal horns, the fore-
brain) and this might be crucial for the observed distinct pain 
sensation. Hence, a greater emphasis on studies of pain in 
humans is strongly recommended [179].
Importantly, previous pain studies were focused on the 
sensory dimension of pain with almost no analysis of the 
affective component of pain, and empathy-like responses in 
experimental animals were, therefore, neglected [183]. The 
affective aspect of pain is still not well-addressed, so there 
is a strong need to study the affective component of pain in 
animal models [182].
Several other factors should be also considered at the pre-
clinical phase as potential factors leading to translational 
failure. Firstly, animal models might not be the best repre-
sentation of the clinical situation and it is of key importance 
to use only the most effective and reliable animal models that 
mimic the clinical situation as close as possible (construct 
validity). Scientists need to be aware of the existence of vari-
ous available models, and how they differ in characteristics 
and efficacy in causing CIPN. In this context, it seems that 
the available animal CIPN models are manifestations of gain 
in sensory functions which measure mainly allodynia, hyper-
algesia and neurophysiological alterations in nerve function, 
whereas many patients, at least in the chronic phase of CIPN 
also report other symptoms, such as numbness, tingling and 
ongoing pain. This may compromise the clinical relevance 
of these animal models for chronic CIPN studies [181, 184]. 
Therefore, the use of animal models that replicate all symp-
toms observed in humans is strongly demanded but is still a 
very challenging endeavor as some symptoms occur spon-
taneously and are very difficult to replicate in animals. At 
present, measures of ongoing pain in rodents is an emerging 
phenomenon.
Another key issue regarding the clinical relevance of ani-
mal models is that the majority of them utilize cancer-free 
animals, whereas in the clinical situation most CIPN patient 
have or experienced previously cancer. Cancer may signifi-
cantly confound the effectiveness (both: pharmacokinetic 
and pharmacodynamics properties) of drugs used for CIPN 
treatment [181, 184].
Also, doses and mode of deliveries of the anti-tumor 
drugs may not reflect the clinical situation, and many 
preclinical studies do not seem to be fully randomized and 
blinded.
Polyneuropathy characteristics is also important and there 
are some serious concerns about the clinical relevance of 
the time courses frequently studied in animals. Acute CIPN 
affects patients within the first 6 months and chronic CIPN 
has been observed in patients approximately 2 years after 
treatment. Therefore, the short duration of the majority of 
animal models of CIPN likely regard the acute phase only 
[181].
Finally, most studies use only male animals and evoke 
limb withdrawal to mechanical stimuli [180, 181]. In the 
clinic, many CIPN-inducing drugs are frequently used to 
treat female cancer patients (e.g., ovarian or breast cancers), 
thus the use of both sexes of animals in the modeling of 
CIPN is warranted and will likely improve the validity of 
animal models [26, 181].
Taken together, it is important to realize that at present no 
animal model represents the full clinical situation perfectly 
because of interspecies differences and inevitable differ-
ences between the conditions created in animals and those 
observed in human CIPN. Research findings, therefore, need 
to be confirmed in multiple animal models as comparable 
results in multiple animal models of CIPN would increase 
our confidence in the results and their applicability for the 
clinical situation.
Since many of the mechanisms that underlie CIPN over-
lap, they may reinforce each other. Hence, combination ther-
apies seem to be potentially useful and valuable approaches 
to prevent CIPN development or treat its symptoms. Unfor-
tunately, at present, the number of clinical trials focused on 
testing combination drug therapies for neuropathic pain is 
scarce, and there are no clear algorithms describing how to 
use combined drugs in neuropathic patients.
Importantly, the patient-reported severity of CIPN symp-
toms are more valuable than the assessments provided by 
clinicians. One should also realize that comorbidities present 
in patient populations in addition to cancer itself are likely 
to influence nociception and CIPN-related neuropathic pain 
pathophysiology. Therefore, a more effective treatment for 
CIPN will require close cooperation between oncologists, 
neurologists, psychiatrists and specialists from other fields of 
medicine to ensure that CIPN patients are effectively cured 
and monitored.
A better understanding of the mechanisms of CIPN is 
important for the identification of novel preventative thera-
pies. Deeper insight into mechanisms underlying axonal 
degeneration in CIPN is, therefore, an urgent need. Since 
degenerative processes within the peripheral nervous system 
are only a part of CIPN, we also need to understand the role 
of central nervous system changes (neuroplasticity and the 
central sensitization of neuropathic pain), neuromodulators, 
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neurotransmitters and receptors implicated in the phenom-
ena that induce CIPN [185].
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